Attend the FiercePharmaMarketing Forum
This is a can't-miss event! Save 15% with promo code FPMF2018
An Indian company that has had its drugs banned by the FDA has bought a contract manufacturing operation in the U.S.
While Big Pharma companies have equivocated about whether to pull production from the U.K. because of Brexit, CDMO Almac quickly went out and did something…
CDMO Cambrex has installed continuous flow manufacturing technology at a site in Sweden where it will make intermediates for AstraZeneca.
The FDA has nailed an Australian contract manufacturer with a warning letter for serious manufacturing and quality lapses.
Swedish CDMO Recipharm has decided to buy the piece of Indian sterile drugmaker Nitin Lifesciences that it doesn’t currently own.
Impax Laboratories will sell its manufacturing site in Taiwan to Bora Pharmaceuticals for $18.5 million and take a charge of up to $80 million.
Novasep, which makes clinical supplies for a new antibiotic being developed by Tetraphase, will now start commercial-scale production.
The public advocacy group Public Citizen has petitioned the FDA to ban an API that it says agency reviewers determined posed safety risks to patients.
China’s WuXi Biologics says its new $150 million, 30,000-liter capacity biologics plant is up and running, a feat it accomplished in less than three years.
Contractor ADC Biotechnology is moving quickly to get a manufacturing facility built in Wales to produce its new ADCs.